Compare RDI & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDI | TXMD |
|---|---|---|
| Founded | 1937 | 2008 |
| Country | United States | United States |
| Employees | 2005 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 24.4M |
| IPO Year | N/A | 2012 |
| Metric | RDI | TXMD |
|---|---|---|
| Price | $1.51 | $2.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 40.6K | 17.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | $209.00 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.94 | $0.99 |
| 52 Week High | $1.65 | $2.95 |
| Indicator | RDI | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 67.55 | 55.49 |
| Support Level | $1.00 | $2.07 |
| Resistance Level | N/A | $2.13 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 100.00 | 71.11 |
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.